grant
Center for Antiviral Medicines & Pandemic Preparedness (CAMPP)
Organization SCRIPPS RESEARCH INSTITUTE, THELocation LA JOLLA, UNITED STATESPosted 16 May 2022Deadline 31 Oct 2026
NIHUS FederalResearch GrantFY20222019 novel corona virus2019 novel coronavirus2019-nCoVAnimal ModelAnimal Models and Related StudiesAntibody TherapyAntiproteasesAntiviral AgentsAntiviral DrugsAntiviral TherapyAntiviralsArchitectureBackBioavailabilityBiologic AvailabilityBiologic ProductsBiological AgentBiological AvailabilityBiological ProductsBreakbone Fever VirusBunyavirusCOVID crisisCOVID epidemicCOVID pandemicCOVID-19 crisisCOVID-19 epidemicCOVID-19 global health crisisCOVID-19 global pandemicCOVID-19 health crisisCOVID-19 infectionCOVID-19 pandemicCOVID-19 public health crisisCOVID-19 therapeuticsCOVID-19 therapyCOVID-19 treatmentCOVID-19 virusCOVID19 crisisCOVID19 epidemicCOVID19 global health crisisCOVID19 global pandemicCOVID19 health crisisCOVID19 infectionCOVID19 pandemicCOVID19 public health crisisCOVID19 therapeuticsCOVID19 therapyCOVID19 treatmentCOVID19 virusCapsidChemicalsChemistryClinicalClinical EvaluationClinical TestingClinical Treatment MoabClinical TrialsCoV-2CoV2Computational BiologyCoronaviridaeCoronavirusDNA HelicasesDNA Unwinding ProteinsDNA unwinding enzymeDengue VirusDengue fever virusDevelopmentDisease OutbreaksDorsumDoseDrug TargetingDrugsEBOVEbolaEbola virusEbola-like VirusesEgypt 101 virusEndopeptidase InhibitorsEngineering / ArchitectureEnsureEquilibriumEsteroproteasesFDA EUAFDA Emergency Use AuthorizationFiloviridaeFilovirusFlavivirusFood and Drug Administration EUAFood and Drug Administration Emergency Use AuthorizationFoundationsFundingFutureGS-5734Gene TranscriptionGenetic TranscriptionGoalsGrantGroup B ArbovirusHealthHumanHuman ResourcesIndividualIndustryInfectionInfrastructureIntentionInterdisciplinary ResearchInterdisciplinary StudyInvestigatorsIon ChannelIonic ChannelsLassa fever virusLassa virusMERSMERS coronavirus diseaseMERS-CoV diseaseManpowerMediatingMedicationMedicineMembrane ChannelsMiddle East Respiratory SyndromeMiddle East Respiratory Syndrome CoV diseaseMiddle East Respiratory Syndrome coronavirus diseaseMiddle Eastern Respiratory SyndromeMiddle Eastern Respiratory Syndrome CoV diseaseMiddle Eastern Respiratory Syndrome coronavirus diseaseModern ManMonoclonal AntibodiesMultidisciplinary CollaborationMultidisciplinary ResearchNon-Polyadenylated RNANucleocapsidNucleosidesOralOrganoidsOrthobunyavirusOutbreaksOutcomePeptidase InhibitorsPeptidasesPeptide Hydrolase InhibitorsPeptide HydrolasesPeptide Peptidohydrolase InhibitorsPharmaceutic PreparationsPharmaceutical AgentPharmaceutical PreparationsPharmaceuticalsPharmacologic SubstancePharmacological SubstancePharmacologyPhysiologic AvailabilityPolymerasePositionPositioning AttributePreparednessProcessProtease AntagonistsProtease GeneProtease InhibitorProteasesProteinase InhibitorsProteinasesProteinsProteolytic EnzymesRNARNA ExpressionRNA Gene ProductsRNA Polymerase InhibitorRNA Synthesis InhibitorsRNA VirusesRNA chemical synthesisRNA synthesisReadinessResearch InstituteResearch PersonnelResearchersRibonucleic AcidRitonavirSARSSARS corona virus 2SARS coronavirus diseaseSARS-CO-V2SARS-COVID-2SARS-CoV diseaseSARS-CoV-2SARS-CoV-2 epidemicSARS-CoV-2 global health crisisSARS-CoV-2 global pandemicSARS-CoV-2 infectionSARS-CoV-2 inhibitorSARS-CoV-2 pandemicSARS-CoV-2 therapeuticsSARS-CoV-2 therapySARS-CoV-2 treatmentSARS-CoV2SARS-CoV2 epidemicSARS-CoV2 infectionSARS-CoV2 pandemicSARS-associated corona virus 2SARS-associated coronavirus 2SARS-coronavirus-2SARS-coronavirus-2 epidemicSARS-coronavirus-2 pandemicSARS-coronavirus-2 therapeuticsSARS-related corona virus 2SARS-related coronavirus 2SARSCoV2Severe Acute Respiratory Coronavirus 2Severe Acute Respiratory Distress Syndrome CoV 2Severe Acute Respiratory Distress Syndrome Corona Virus 2Severe Acute Respiratory Distress Syndrome Coronavirus 2Severe Acute Respiratory SyndromeSevere Acute Respiratory Syndrome CoV 2Severe Acute Respiratory Syndrome CoV 2 epidemicSevere Acute Respiratory Syndrome CoV 2 pandemicSevere Acute Respiratory Syndrome CoV diseaseSevere Acute Respiratory Syndrome coronavirus diseaseSevere Acute Respiratory Syndrome-associated coronavirus 2Severe Acute Respiratory Syndrome-related coronavirus 2Severe Fever with Thrombocytopenia Syndrome VirusSevere Fever with Thrombocytopenia virusSevere acute respiratory syndrome associated corona virus 2Severe acute respiratory syndrome corona virus 2Severe acute respiratory syndrome coronavirus 2Severe acute respiratory syndrome coronavirus 2 epidemicSevere acute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 inhibitorSevere acute respiratory syndrome coronavirus 2 pandemicSevere acute respiratory syndrome coronavirus 2 therapeuticsSevere acute respiratory syndrome related corona virus 2Structural ProteinStructureTechnologyTestingTherapeuticTranscriptionVekluryViralViral DiseasesViral Gene ProductsViral Gene ProteinsViral ProteinsVirusVirus DiseasesWNVWest NileWest Nile virusWorkWuhan coronavirusZIKAanti-viral agentsanti-viral compoundanti-viral developmentanti-viral drug developmentanti-viral drugsanti-viral medicationanti-viral therapeuticanti-viral therapeutic developmentanti-viral therapyanti-viral therapy developmentanti-viralsantibody based therapiesantibody treatmentantibody-based therapeuticsantibody-based treatmentantiviral compoundantiviral developmentantiviral drug developmentantiviral medicationantiviral therapeuticantiviral therapeutic developmentantiviral therapy developmentbalancebalance functionbasebiologicsbiopharmaceuticalbiopharmaceutical companybiopharmaceutical industrybiotherapeutic agentblock SARS-CoV-2block severe acute respiratory syndrome coronavirus 2chemical librarychemoproteomicsclinical developmentclinical testcomputer biologycorona viruscorona virus disease 2019 epidemiccorona virus disease 2019 pandemiccoronavirus disease 2019 crisiscoronavirus disease 2019 epidemiccoronavirus disease 2019 global health crisiscoronavirus disease 2019 global pandemiccoronavirus disease 2019 health crisiscoronavirus disease 2019 infectioncoronavirus disease 2019 pandemiccoronavirus disease 2019 public health crisiscoronavirus disease 2019 therapeuticscoronavirus disease 2019 therapycoronavirus disease 2019 treatmentcoronavirus disease 2019 viruscoronavirus disease crisiscoronavirus disease epidemiccoronavirus disease pandemiccoronavirus disease-19 global pandemiccoronavirus disease-19 pandemiccoronavirus disease-19 virusdeveloping anti-viral agentdeveloping anti-viral drugdeveloping anti-viral therapeuticdeveloping anti-viral therapydeveloping antiviral agentdeveloping antiviral drugdeveloping antiviral therapeuticdeveloping antiviral therapydevelopmentaldrug candidatedrug developmentdrug discoverydrug/agentebolavirusemergency use authorizationflexibilityflexiblehCoV19helicasehemorrhagic fever virushigh riskhuman diseasein vivoinfected with COVID-19infected with COVID19infected with SARS-CoV-2infected with SARS-CoV2infected with coronavirus disease 2019infected with severe acute respiratory syndrome coronavirus 2inhibit SARS-CoV-2inhibit severe acute respiratory syndrome coronavirus 2inhibitorinnovateinnovationinnovativeinterdisciplinary approachlead optimizationmAbsmodel of animalmodel organismmolnupiravirmortalitymultidisciplinarymultidisciplinary approachnCoV2new approachesnext generationnorvirnovelnovel approachesnovel strategiesnovel strategynucleoside inhibitorpandemicpandemic diseasepandemic preparednesspersonnelpre-clinicalpre-clinical studypreclinicalpreclinical studyprogramsremdesivirresearch clinical testingscreeningsevere acute respiratory syndrome coronavirus 2 global health crisissevere acute respiratory syndrome coronavirus 2 global pandemicsevere acute respiratory syndrome coronavirus 2 therapysevere acute respiratory syndrome coronavirus 2 treatmentsmall molecule librariesstructural biologysuccesstherapeutics against COVID-19therapeutics against COVID19therapeutics against SARS-CoV-2therapeutics against SARS-coronavirus-2therapeutics against Severe acute respiratory syndrome coronavirus 2therapeutics against coronavirus disease 2019therapeutics for novel coronavirustreat COVID-19treat COVID19treat SARS-CoV-2treat coronavirus disease 2019treat severe acute respiratory syndrome coronavirus 2treatment centerviral infectionviral infectious disease treatmentvirologyvirus infectionvirus proteinvirus-induced disease
Description preview
SUMMARY
The ongoing COVID-19 pandemic has brought to light an urgent need to enhance the therapeutic preparedness
for future viral outbreaks and pandemics. The overarching goal of the “Center for Antiviral Medicines &
Pandemic Preparedness” (CAMPP) is thus to develop novel strategies and enhance the drug discovery
pipelines for direct-acting…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click